-
Cop: What epidemic prevention inspiration does the new crown secondary infection bring?
Time of Update: 2020-09-27
A report published on the website of the American journal Science quoted Angela Rasmussen, a virologist at Columbia University, as saying that the second infection may be a rare case of a first infection that does not produce a good immune response, "I don't think it has a significant impact on vaccines and immunity." have also observed secondary infections in studies of other coronavirus.
-
The rare disease drug agaga sugarase alpha injection with a strong solution was approved to enter China.
Time of Update: 2020-09-26
Medicine Network August 31 - Takeda China announced on the 28th that its innovative drug Ripja (Aga glycosin alpha injection with a thick solution) approved by the State Drug Administration, for the diagnosis of Fabre disease (alpha-semi-lactose glycosidease A deficiency) patients with long-term enzyme replacement treatment.
-
The first 癀 class 1 new drug approved clinical sword refers to solid tumors.
Time of Update: 2020-09-25
Pharma Network September 1st, recently, announced that the company's class 1 chemical innovation drug PZH2111 tablets approved by the State Drug Administration to carry out clinical trials.
the second half of this year, a total of two chemical class 1 new drugs declared clinical, respectively, PZH2109 capsules, PZH2111 tablets.
-
Aceh Pharmaceutical Bcl-2 inhibitor APG-2575 has been approved by the FDA orphan drug for the treatment of chronic lymphocytic leukemia.
Time of Update: 2020-09-20
Introduction: Aceh Pharmaceutical Bcl-2 inhibitor APG-2575 has been qualified by the FDA orphan drug for the treatment of chronic lymphocytic leukemia (CLL).
HK) today announced that the U.S. Food and Drug Administration (FDA) has awarded the company the qualification of the original innovative drug Bcl-2 inhibitor APG-2575 orphan drug for the treatment of chronic lymphocytic leukemia (CLL).
-
Thermo Technology joins INOVIO's global production alliance.
Time of Update: 2020-09-20
with a coalition of third-party manufacturers, INOVIO plans to produce 100 million doses of the INO-4800 vaccine by 2021, but this will require FDA approval of the INO-4800 as the new coronary pneumonia vaccine.
-
Johnson and Johnson BTK inhibitor Ibtini Unilitoxi monoantigen monotherapy CLL has been approved in Europe.
Time of Update: 2020-09-20
Domestically, Ibdinib (commodity name: Eythaya ®) was approved in 2017 for the treatment of adult chronic CLL/small lymphocyte lymphoma (SLL) patients who have received at least one treatment in the past, as well as patients with set cell lymphoma (MCL) who have received at least one treatment in the past, as innovative targeted oral drugs for the treatment of lymphoma subsypes.
-
Excientia has teamed up with East China Pharmaceuticals to accelerate the development of anti-tumor drugs through artificial intelligence.
Time of Update: 2020-09-20
9, 2020 /XINHUA/ -- Exscientia, the world's leading artificial intelligence (AI) drug research and development company, and East China Pharmaceuticals today announced that they have established a partnership to accelerate the discovery of breakthrough innovative therapies for small molecule drugs in the field of oncology.
-
Zeng more than $2.5 billion of the first blood lipid regulator Hunan Pharmaceutical Company will take the first imitation.
Time of Update: 2020-09-20
Pharmaceutical network September 9th, a few days ago, Hunan Fangsheng Pharmaceuticals to copy the 4 categories of reported wheat cereal tablets into the administrative approval stage, the original research products have been sold more than 2.5 billion U.S. dollars a year, the current domestic market has not been generic drugs listed for sale.
-
The study found that a commonly used drug increased the risk of Alzheimer's disease.
Time of Update: 2020-09-20
XINHUA News Agency, Beijing, September 7 (Xinhua) -- "Reference News" published on the U.S. Daily Science Website on the 7th" related to the increased risk of Alzheimer's disease commonly used drugs.
-
HKC has developed the world's first nasal spray vaccine and has been approved for clinical trials!
Time of Update: 2020-09-19
September 9, the National Key Laboratory for New Infectious Diseases in the Department of Microbiology of the Faculty of Medicine of the University of Hong Kong announced that the new crown vaccine for influenza virus vectors developed with Xiamen University and Beijing Wantay Biometrics has been approved by the State Drug Administration to conduct clinical trials.
-
Latest! Several new crown vaccines from around the world have entered Phase III clinical trials, and mass vaccinations in Russia have been launched.
Time of Update: 2020-09-19
Read: WHO: There are 9 new crown vaccines in Phase III clinical trials worldwide, with China accounting for 4. the world's new crown epidemic continues to develop, India's growing number of confirmed
-
Multinational pharmaceutical executives out of the season: BMS head of oncology research and development joins Blueprint, AbbVie veteran magenta ...
Time of Update: 2020-09-19
Nocion Therapeutics, a start-up focused on the development of sodium ion channel blocker-type analgesics, is now bringing its first new drug project, NOC-100 (NTX-1175 of inhalant form), to clinical use.
-
CDMO List: "2020 China CDMO Enterprise Top 20" grandly released!
Time of Update: 2020-09-19
Guide: Leading the future, 20 CDMO enterprise tree industry benchmark. CMO refers to providing pharmaceutical companies with services such as process development and API production required for the p
-
AGC Biologics expands its partnership with Novavax.
Time of Update: 2020-09-04
AMC Biologics is currently preparing to manufacture Matrix-M™ at its Copenhagen facility, which is part of the Avavac coronavirus vaccine NVX-CoV2373.
mark Womack, chief commercial officer at AMC Biologics, said: "We are very pleased that Novavax has asked us to expand production of its coronavirus vaccine NVX-CoV2373 in Seattle.
-
100% recovered and discharged from the hospital! Coagulant pathway inhibitor treatment COVID-19 showed strong efficacy.
Time of Update: 2020-09-04
Omeros recently released the results of a sympathetic drug study on the treatment of patients with COVID-19 acute respiratory distress syndrome (ARDS) at narsoplimab.
-
New ADC drugs for the treatment of platinum-resistant ovarian cancer are fda fast-tracked.
Time of Update: 2020-09-04
. On August 11, local time, Mersana Therapeutics, a U.S. biopharmaceutical company, announced that its antibody-coupled drug (ADCs) XMT-1536 was awarded fast-track status by the FDA for the treatment of platinum-resistant high-level slurry ovarian cancer.
-
Tax credits inspire enthusiasm for drug research and development for rare diseases.
Time of Update: 2020-09-03
Medicine Network August 14 - Rare diseases usually have a low incidence, a wide variety, mostly due to genetic defects. , there is a lack of systematic research and summary of the pathogenesis and tre
-
AGC Biologics has teamed up with Ono Pharmaceuticals as CDMO.
Time of Update: 2020-09-03
, Aug. 13, 2020 /AGENCY/-- CDMO AGC Biologics announced that it has teamed up with Ono Pharmaceutical Co., Ltd. to produce new and innovative biopharmaceers in clinical development.
-
Chinese experts have found that biomarkers of Alzheimer's disease can be predicted five to seven years in advance.
Time of Update: 2020-09-03
Medicine Network August 14 - Alzheimer's disease has become a serious harm to the health and quality of life of the world's elderly, reporters recently learned from the Capital Medical University Xuanwu Hospital, the hospital Professor Jia Jianping team found that the symptoms can be predicted 5 to 7 years before the emergence of biological markers of Alzheimer's disease.
-
Metformin has a new effect
Time of Update: 2020-09-03
18, or can reduce adverse glucosticogen reactions Recently, The Lancet - Diabetes and Endocrinology published a study - the results of a phase 2 clinical trial, metformin for patients with chronic inflammatory diseases, can improve metabolic health, reduce the serious side effects of glucosin therapy.
